Skip to main content

Table 1 Temporomandibular disorders pain characteristics of the study population

From: Antinuclear antibody and rheumatoid factor positivity in temporomandibular disorders

 

Total patients (n = 257)

Male patients (n = 51)

Female patients (n = 206)

ANA/RF (+)

(n = 39)

ANA/RF (−)

(n = 218)

P-value

ANA/RF (+)

(n = 4)

ANA/RF (−)

(n = 47)

P-value

ANA/RF (+)

(n = 35)

ANA/RF (−)

(n = 171)

P-value

Pain duration (months)a

12 (1.5–36)

3 (0.8–24)

0.117

27 (3.8–48)

3 (0.8–27)

0.233

12 (1–33)

3.5 (0.8–24)

0.215

Pain intensitya

45.0 (23.3–67.5)

46.7 (30–60)

0.822

48.3 (22.5–69.2)

47 (23.3–60)

0.699

45 (23.3–67.5)

46.7 (30–60)

0.620

Disability daysa

4.5 (0–100)

10 (0–40)

0.454

100 (12.5–165)

10 (0–90)

0.355

4 (0–47.5)

10 (0–32.5)

0.260

NRS beforea

6 (3–7)

5 (3–7)

0.384

6 (3.5–7.8)

5 (2.3–6)

0.244

6 (3–7)

5 (3–7)

0.723

NRS > 5b

26/39 (66.7%)

117/205 (57.1%)

0.292

3/4 (75%)

23/43 (53.5%)

0.617

23/35 (65.7%)

94/162 (58.0%)

0.452

Pain on openingb

20/39 (51.3%)

114/213 (53.5%)

0.862

2/4 (50%)

20/46 (43.5%)

1.000

18/35 (51.4%)

94/167 (56.3%)

0.709

Pain on eccentric movementb

20/39 (51.3%)

98/214 (45.8%)

0.602

2/4 (50%)

21/46 (45.7%)

1.000

18/35 (51.4%)

77/168 (45.8%)

0.580

Comorbidityb

19/39 (48.7%)

111/214 (51.9%)

0.731

1/4 (25%)

19/46 (41.3%)

0.641

18/35 (51.4%)

92/168 (54.8%)

0.852

CMOa

35 (30–46)

41 (32–47.3)

0.092

38.5 (28.5–41.8)

47 (42–54)

0.033*

33 (30–46)

39 (30–46)

0.479

MMOa

44 (33–49)

46 (40–50.3)

0.111

42 (31.5–48.8)

51 (47–55)

0.016*

44 (33–49)

45 (38–49)

0.783

Capsule palpationa

0 (0–1)

0 (0–2)

0.525

0.5 (0–4.8)

0 (0–1)

0.380

0 (0–1)

0 (0–2)

0.261

Muscle palpation

-masticatorya

2 (0–7)

3 (0–6)

0.689

7.5 (1.5–9.8)

1 (0–4)

0.071

2 (0–6)

3 (1–6)

0.155

Muscle palpation

-necka

0 (0–4)

0 (0–2)

0.279

3 (0.5–7)

0 (0–1)

0.022*

0 (0–4)

0 (0–2)

0.861

  1. ANA, antinuclear antibody; RF, rheumatoid factor; NRS, numeric rating scale; NRS before, NRS before treatment initiation; CMO, comfortable mouth opening; MMO, maximum mouth opening; Palpation, number of muscle that showed a positive response on palpation; Comorbidity, presence of at least one comorbidity
  2. Pain intensity scores were calculated based on answers to the RDC/TMD Axis II questionnaire (mean score of question #7, 8, 9,10)
  3. aDifferences between group means were tested with Mann-Whitney test: Median (lower quartile - upper quartile)
  4. bDifferences between group means were tested with Chi-square test: number of subjects with a positive response/total number of subjects (percentage of subjects with a positive response)
  5. *Significant difference: p < 0.05